Coralville, IA, May 18, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Charles Link, M.D., FACP to its Board of Directors.

“The addition of Dr. Link to our Board of Directors is significant in value. As a practicing oncologist with extensive entrepreneurial experience and industry leadership in key management positions, Dr. Link brings deep expertise and an oncology focus to Viewpoint as we continue to drive our development programs into the clinic towards commercialization. Over the course of his medical and industry careers, Chuck has established a noteworthy track record spanning drug discovery and building early-stage companies to commercialization, and we are excited to leverage his knowledge and expertise,” commented Frances Johnson MD, Chief Medical Officer and Acting CEO of Viewpoint.

Dr. Link is a renowned oncologist and industry leader with over 21 years of experience. He was a practicing oncologist for 18 years, most recently at Medical Oncology and Hematology Associates of Iowa from 1995 to 2013. He also served as director of the Human Gene Therapy Research Institute, which is part of the John Stoddard Cancer Center at Iowa Methodist Medical Center. Most recently, he served as the Co-founder and previous Chairman and Chief Executive Officer of NewLink Genetics, a pioneering immunotherapy company that discovered, developed and commercialized novel immuno-oncology product candidates, including checkpoint inhibitors and cellular immunotherapies. Over the course of his career, Dr. Link successfully completed multiple deals in excess of hundreds of millions of dollars with companies such as Novartis and Roche. Additionally, Dr. Link led the collaborative development of Merck’s EVERBO, the first Ebola vaccine to receive approval from the U.S. Food and Drug Administration. He has authored more than 170 scientific articles and abstracts and has received funding for his research from organizations such as the National Institutes of Health, National Cancer Institute, American Cancer Society, U.S. Army Breast Cancer Grant, and the Susan G. Komen Breast Cancer Foundation.

Dr. Link added, “I am pleased to be joining the board of Viewpoint. Their innovative lead-212-based alpha-particle therapeutics and complementary diagnostic imaging agents have the potential to be transformative for cancer patients. These novel compounds have a significant potential to help patients for whom no therapy currently exists. Hopefully my experience can help the terrific Viewpoint team unlock their full potential and power these important new classes of cancer therapeutics forward.”

Dr. Link was appointed to the United States Airforce Academy, prior to entering Stanford University School of Medicine. Chuck went on to complete his residency in Internal Medicine at the University of California San Francisco. His fellowship training in medical oncology was completed at the National Cancer Institute in Bethesda, Maryland, where he also served as an attending physician.

About Viewpoint

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website viewpointmt.com.

​
Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
viewpoint@jtcir.com

Coralville, IA, May 3, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Frank Morich, M.D., Ph.D., to its Board of Directors.

Dr. Morich is a well-established biopharmaceutical industry leader with over 35 years of executive leadership experience. He currently serves on the board of directors for CUE Biopharma, and since 2020 as the Chairman of the board. Additionally, from 2015 to 2020 he served on the board of Morphosys, and from 2004-2010 he served as a board member for Innate Pharma, both clinical-stage biotechnology companies specializing in antibody development.

“We are excited to have Frank join our Board of Directors. He is an industry veteran with an impressive background with multiple successes spanning his career, including having most recently served as the Chief Commercial Officer of Takeda Pharmaceutical Company, where he was responsible for successfully launching Takeda’s first new cancer product (Adcetris) outside the USA in more than 20 years. As we work to advance what we believe are cutting-edge radiopharmaceutical oncology programs, we believe Frank’s insight and guidance will prove to be invaluable,” commented Frances Johnson, MD, Chief Medical Officer and Acting CEO of Viewpoint.

Prior to pivoting his leadership roles to Board of Director roles, from 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and, from 2010 to 2011, he served as Executive Vice President, International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development.

“Viewpoint continues to demonstrate drive and innovation with their lead-212-based alpha-particle theranostics. Their technologies and therapeutic development have positioned them to address significant unmet needs in the current cancer therapy landscape and potentially optimize patient care, which I believe is of utmost importance,” added Dr. Morich.

Dr. Morich received his M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. Prior to starting his career in industry, Dr. Morich served as a military physician.

About Viewpoint

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions. For more information, please visit the Company’s website viewpointmt.com.

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
viewpoint@jtcir.com